BioCrea / BioCrea Wins The Epilepsy Innovation Seal of Excellence Award . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Radebeul, Germany, January 9, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist validated through pharma partnerships, announced today that the Epilepsy Foundation (Maryland, US) has presented the Epilepsy Innovation Seal of Excellence Award to BioCrea in recognition of the creation of the new anti-seizure platform, Novel Long Term Effective GABA(A) PAMs (LT GABA(A) PAM), to treat refractory epilepsy.
"We are delighted to receive the prestigious SEAL award," said Dr. Tom Kronbach, CEO of BioCrea. "This recognition by the Epilepsy Foundation for our work on the LT GABA(A) PAM platform is highly appreciated. We are impressed that the Foundation's Scientific Advisory Board and Business Advisory Board do see the potential for our platform to deliver efficacious and novel epilepsy treatments which are currently at candidate selection stage. Having successfully delivered novel treatments for partners such as Pfizer, GlaxoSmithKline, Wyeth and Boehringer Ingelheim, we are well placed to further build our portfolio of projects."
The Epilepsy Foundation stated in a letter to BioCrea: "This award is based on the enthusiasm of the Epilepsy Foundation's Scientific Advisory Broad and Business Advisory Board for the present accomplishments and future potential of this new drug platform that we hope will alleviate the suffering of persons with epilepsy."
BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychotic disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). BioCrea was awarded Top Innovator status of the "Top 100" Most Innovative Companies in Germany 2012 by compamedia GmbH.
About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with 47 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The Foundation works to prevent, control and cure epilepsy through community services; public education; federal and local advocacy; and supporting research into new treatments and therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit: www.epilepsy.com.
Dr. Tom Kronbach
CEO, BioCrea GmbH
Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216
Press Release PDF: http://hugin.info/156612/R/1753539/591527.pdf
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BioCrea via Globenewswire
--- End of Message ---
BioCrea GmbH Radebeul Germany
http://www.biocrea.com (END) Dow Jones Newswires
January 09, 2014 03:00 ET (08:00 GMT)- - 03 00 AM EST 01-09-14
Mehr zum NASDAQ Composite Index
Heute im Fokus
Zerschlagung von Wells Fargo gefordert. Tesla: Autopilot schuldlos an Unfall auf deutscher Autobahn. Monopolkommission erwartet lange Prüfung von Bayers Monsanto-Kauf. Fed-Chefin: Ankauf von Aktien und Bonds könnte bei Abschwung helfen. va-Q-tec schlägt Aktien in der Mitte der Preisspanne los.